Chimeric OspA Vaccine Broadens Borrelia Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Lyme disease vaccines are limited in their ability to provide broad protection against various Borrelia species, particularly in Europe where multiple genospecies of Borrelia burgdorferi sensu lato are prevalent, due to heterogeneity in OspA sequences.
Innovation Solution
Development of chimeric OspA molecules that combine proximal and distal portions from different OspA serotypes, encoded by nucleic acid sequences with high sequence identity, to create stable and immunogenic antigens that can be expressed in E. coli for use in a combination vaccine covering all six prevalent serotypes associated with Lyme disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a monovalent OspA-based vaccine is used, then protection against Lyme disease is achieved, but broad protection against multiple Borrelia species is limited due to sequence heterogeneity
Solution Approach 1:
The patent combines OspA sequences from multiple Borrelia species (B. burgdorferi s.s., B. afzelii, and B. garinii) into chimeric constructs. Specifically, it merges the N-terminal region (amino acids 1-190) from one species with the C-terminal region (amino acids 191-317) from another species, creating hybrid antigens that elicit cross-protective immune responses against multiple serotypes and genospecies.
Solution Approach 2:
The chimeric OspA constructs are designed to serve multiple protective functions simultaneously. The vaccine compositions can protect against at least two different genospecies of Borrelia, and the patent describes compositions that provide protection against B. burgdorferi s.s., B. afzelii, and B. garinii, making a single vaccine formulation universally effective across diverse geographic regions and species.
2Adaptability or versatility
If OspA sequences from different serotypes are combined to broaden protection, then vaccine versatility improves, but molecular heterogeneity increases
Solution Approach 1:
The OspA protein is divided into two functional segments: the N-terminal region (amino acids 1-190) which contains the lipidation site and structural domain, and the C-terminal region (amino acids 191-317) which contains the protective epitopes. By segmenting the protein and recombining these segments from different species, the patent reduces the complexity of creating entirely new heterogeneous proteins while still achieving broad serotype coverage.
Solution Approach 2:
The patent applies local quality by maintaining the conserved N-terminal region from a single species (providing structural stability and lipidation) while introducing variability in the C-terminal region from multiple species (providing diverse protective epitopes). This localized approach to heterogeneity allows the vaccine to cover multiple serotypes without the complications of complete molecular heterogeneity throughout the entire protein structure.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.